Levosimendan

• Description :

  Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

• Product Name Alternative :

  Simsndan; OR-1259

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; Phosphodiesterase (PDE) ; Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Levosimendan.html

• Purity :

  99.82

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C1C[C@@H](C)C(C2=CC=C(N/N=C(C#N)/C#N)C=C2)=NN1

• Molecular Formula :

  C14H12N6O

• Molecular Weight :

  280.28

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5 (4) : p. 227-245.|[2]Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159 (2) : p. 82-7.|[3]Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40 (2) : p. 634-46.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [141505-33-1]